Rasha Aboelhassan: Solving debates for the treatment of stage III inoperable lung cancer is challenging
“For decades, solving debates for the treatment of stage III inoperable lung cancer is challenging between radiation, chemotherapy therapy, and immunotherapy.
Yesterday, me and Prof Hesham Abbas faced this challenge:
We discussed each other’s debates in Pacific trial publication as well as all debates made in ESMO, ASCO, and IASLC.
The surprise was that audiences from Africa, Yaman, as well as Egypt, young oncologists who decided to participate the same debates apply treatment in their own countries,
I was proud and overwhelmed at the same time!
How can Egypt help all oncologists from all over the world?
I decided to continue my presentation in an interactive way to know the strategies that come from all countries and solve their debates.
Finally, we stated that we need to fit Pacific protocol for the patients who will have more clinical benefits and that early diagnosis of lung cancer will improve the costs benefit ratio for all countries.
the final as well as early voting for Pacific trial is showing that we still need more efforts in research to solve debates.
Thanks for all Astrazeneca team who sponsored scientific activity.”
Source: Rasha Aboelhassan/LinkedIn
Rasha Aboelhassan is a Senior Oncology Consultant at Nasser Institute Hospital. In addition to her clinical role, she volunteers as a reviewer for the World Journal of Surgical Oncology, contributing to advancements in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023